Adaptive Biotechnologies says FDA issues EUA for T-Detect COVID » 18:4703/0503/05/21
Adaptive Biotechnologies (ADPT) announced that the U.S. FDA issued an Emergency Use Authorization for T-Detect COVID to confirm recent or prior COVID-19 infection. This first-in-class T cell- based test is the first indication resulting from Adaptive's TCR-Antigen Map collaboration with Microsoft (MSFT).
30K U.S. groups hacked via Microsoft email software flaws, KrebsOnSecurity says » 17:0703/0503/05/21
No fewer than 30,000…
No fewer than 30,000 organizations across the U.S., including a large number of small businesses, towns, cities, and local governments, have in the past few days been hacked by an aggressive Chinese cyber espionage unit centered on stealing email from victim organizations, KrebsOnSecurity reports, citing multiple sources. The espionage unit is exploiting four newly-found flaws in Microsoft (MSFT) Exchange Server email software, and has seeded hundreds of thousands of victim organizations globally with tools that give hackers total remote control over impacted systems, the report says. Such recent hacks may well end up far eclipsing the damage done by the SolarWinds (SWI) hacks, the report notes. Reference Link
EMA says bamlanivimab can be considered as monotherapy treatment for COVID-19 » 11:1603/0503/05/21
The EMA's human…
The EMA's human medicines committee, or CHMP, has completed its review on the use of Eli Lilly's monoclonal antibodies bamlanivimab and etesevimab to treat patients with COVID-19, announced the EMA. "The Agency concluded that bamlanivimab and etesevimab can be used together to treat confirmed COVID-19 in patients who do not require supplemental oxygen and who are at high risk of their COVID-19 disease becoming severe. The Agency also looked at the use of bamlanivimab alone and concluded that, despite uncertainties around the benefits of monotherapy, it can be considered a treatment option," the EMA announced. Reference Link
Take-Two CEO says players 'ready for $70 games,' VGC reports » 11:1203/0503/05/21
TTWO, MSFT, SNE
Take-Two (TTWO) CEO…
Take-Two (TTWO) CEO Strauss Zelnick reiterated his company's view that the move to charge $70 instead of $60 for the Xbox Series X (MSFT) and PlayStation 5 (SNE) versions of "NBA 2K21" was the right one, since the public was "ready" for the price hike, VGC's Chris Scullion reports, citing comments from the Morgan Stanley Technology, Media & Telecom Conference. "We announced a $70 price point for NBA 2K21, our view was that we're offering an array of extraordinary experiences, lots of replayability, and the last time there was a frontline price increase in the US was 2005, 2006, so we think consumers were ready for it," Zelnick said. The CEO did not seem to suggest, though, that all future games will cost $70 going forwards, instead saying the company needs to focus on providing a level of content that justifies that price point, the author notes. Reference Link
Microsoft price target raised to $290 from $285 at Morgan Stanley » 07:1903/0503/05/21
Morgan Stanley analyst…
Morgan Stanley analyst Keith Weiss raised the firm's price target on Microsoft to $290 from $285 and keeps an Overweight rating on the shares, arguing that Microsoft is well positioned to gain an even larger share of the IT wallet, particularly as Cloud adoption picks up in larger enterprises. However, unlike a "breadth of well secularly positioned stocks in software," Microsoft's valuation "remains very attractive," setting up an attractive buying opportunity, Weiss tells investors.
Eli Lilly research and development group publishes pirtobrutinib trial data » 06:4803/0503/05/21
Loxo Oncology at Lilly, a…
Loxo Oncology at Lilly, a research and development group of Eli Lilly, announced that The Lancet has published data from the pirtobrutinib global Phase 1/2 BRUIN clinical trial in relapsed or refractory chronic lymphocytic leukemia, or CLL, small lymphocytic lymphoma, or SLL, mantle cell lymphoma, or MCL and other non-Hodgkin's lymphomas. Pirtobrutinib is an investigational, highly selective, non-covalent Bruton's tyrosine kinase, or BTK, inhibitor. The data in the publication include key findings previously presented at the 2020 American Society of Hematology. The publication includes safety and efficacy data for 323 relapsed or refractory patients that were enrolled to the BRUIN Phase 1/2 trial as of September 27, 2020.
Mizuho healthcare analysts to hold an analyst/industry conference call » 04:5503/0503/05/21
Analysts discuss Eli…
Analysts discuss Eli Lilly's Alzheimer's Disease Drug, Donanemab and the real-world clnical implications with Paul R. Solomon, PhD on an Analyst/Industry conference call to be held on March 5.
Repare Therapeutics reports Q4 EPS ($2.66), consensus (39c) » 16:1303/0403/04/21
Cash and cash…
Cash and cash equivalents, restricted cash and marketable securities as of December 31, 2020 were $333.9M. "We met or exceeded key business and program milestones in 2020. In the first half, we secured more than $300 million in new balance sheet capital from our IPO and from the up-front payments associated with our Bristol Myers Squibb collaboration, all of which we believe will accelerate program progress. In the second half, we continued to execute on our strategic goals by successfully launching our Phase 1/2 clinical trial for RP-3500, which is currently enrolling patients. 10 sites have been activated across North America and Europe," said Lloyd M. Segal, CEO. "We continue to advance our discovery platform and have now designated our second clinical program, RP-6306, for which we have initiated IND-enabling studies."
Microsoft president Smith to testify at 'Big Tech' antitrust hearing, Axios says » 14:0503/0403/04/21
MSFT, AMZN, AAPL, GOOG, FB
The House Judiciary…
The House Judiciary antitrust subcommittee will be holding hearings this spring on antitrust issues and "Big Tech," as a follow up to the inquiries the government started a last year, wrote Ashley Gold for Axios. According to Axios, the Microsoft (MSFT) president Brad Smith, a proponent of anti- trust measures for "Big Tech" companies, will be testifying "before a House antitrust subcommittee hearing next Friday on the Big Tech antitrust issue and the media, added Axios. The Fly notes that the companies usually associated with "Big Tech" include Amazon (AMZN), Apple (AAPL), Google (GOOG), Facebook (FB) and Microsoft. Reference Link
Fly Intel: What to watch in Slack earnings report » 11:1603/0403/04/21
WORK, CRM, MSFT
Slack Technologies (WORK)…